Pava Partners advised the founders and shareholders of Synaptikon GmbH (“Synaptikon”), the company behind the Digital Health Application NeuroNation MED and the NeuroNation brand, on a strategic investment by the Schwabe Group (“Schwabe”).

With over 30 million users worldwide, Synaptikon is one of the leading providers of digital cognitive interventions. The NeuroNation MED app is permanently approved as a Digital Health Application (DiGA) and can be prescribed by physicians and psychotherapists.

Schwabe is a corporate group comprising several companies in the pharmaceutical and healthcare industries. For all member companies, plants serve as the primary source material for the development of pharmaceuticals and health supplements. The group’s total revenue amounts to approximately €950 million, and it currently employs around 4,000 people worldwide, including approximately 1,400 in Germany.

With this investment, Schwabe is expanding its expertise in the field of digital health solutions. The shared vision goes beyond symptom relief. In the long term, the goal is to develop disease-modifying therapies for mild cognitive impairment (MCI) and similar conditions that combine cognitive training, exercise, nutrition, and pharmacological support. These therapeutic and preventive approaches will be made accessible to as many patients worldwide as possible through personalized, digital formats as part of a holistic approach. An estimated 320 million people worldwide live with MCI, approximately 95 percent of whom remain undiagnosed.

“With NeuroNation, we became the first app in Germany to be prescribed by a doctor, and with NeuroNation MED, we have developed a Digital Health Application (DiGA) specifically designed for people with acquired or neurodegenerative mild cognitive impairments, as well as their treating physicians or psychotherapists. Currently, NeuroNation MED is used by approximately 25% of patients with mild cognitive impairment (ICD-10 F06.7). True to the motto ‘digital before outpatient before inpatient,’ our goal is to establish the first holistic digital therapy platform for cognitive and mental health,” says Jakob Futorjanski. Together with Rojahn Ahmadi, the two founders and managing directors run Synaptikon.

The synergy between Synaptikon and Schwabe can make a decisive contribution to strengthening education and awareness about MCI. Schwabe’s scientific depth, regulatory experience, and decades of trust, combined with Synaptikon’s agility, user-centricity, and technological expertise, create the conditions to narrow this care gap on a relevant scale.

Synaptikon on Pava Partners

“The Pava team was always extremely well prepared, consistent, and goal-oriented – before, during, and after the process. This is our second transaction with Kevin Kissner and his team, and it certainly won’t be our last. On behalf of all stakeholders, I would like to thank Kevin and the team at Pava Partners. Thanks to their outstanding market expertise, excellent network, and structured process management, we have found the ideal strategic partner for the next phase of growth in the Schwabe Group, even in a highly competitive process,” says Jakob Futorjanski, Co-founder and CEO of Synaptikon.

About Synapticon

Synaptikon GmbH was founded in Berlin in 2011 and develops digital solutions to promote cognitive health. With over 30 million users worldwide, the company is one of the leading providers of digital cognitive interventions. The NeuroNation MED app is permanently approved as a Digital Health Application (DiGA) and can be prescribed by physicians and psychotherapists (PZN: 18787822). It is intended for people with mild cognitive impairment (ICD-10: F06.7) – such as that resulting from acquired and neurodegenerative neurological, internal, or oncological underlying conditions. The multimodal training program comprises 23 interactive, personalized exercises and is based on scientific findings from clinical studies. NeuroNation MED is available in German and English and is continuously being developed in collaboration with research institutions such as Charité Berlin, Jena University Hospital, and the University of Cologne.

For more information, visit www.neuronation.com.

About Schwabe Group

The Schwabe Group is a corporate group comprising several companies in the pharmaceutical and healthcare industries. For all member companies, plants serve as the primary source material for the development of pharmaceuticals and health supplements. The group’s total revenue amounts to approximately €950 million. Founded in Leipzig in 1866, the group has been active globally for 160 years and today employs around 4,000 people worldwide, including approximately 1,400 in Germany. Its headquarters are located in Karlsruhe.

For more information, visit www.schwabe-group.com.